[Synchronous primary cancer of the endometrium and ovary]

Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):617-20.
[Article in Chinese]

Abstract

To investigate the clinical and pathological characteristics, treatment, and The data of 12 patients prognosis of synchronous primary cancer of the endometrium and ovary. Methods with synchronous primary cancer of the endometrium and ovary were retrospectively reviewed . Results Eight patients had the same histological type of endometrioid carcinoma in both uterus and ovary, 4 patients had different histological types in uterus and ovary. Synchronous primary cancer of the endometrium and ovary was difficult to be dignosed preoperatively. All ovarian tumors were small with an average diameter of 7 cm. Infertility was common among these patients(40.7%). Most of them had early stage I lesion (66.7%). endometrioid carcinomas was the main pathologic type (66.7%). All patients were treated surgically followed by chemotherapy with a 3-year survival rate of 66.7% (8/12).

Conclusion: Synchronous primary endometrium and ovary cancer is a specific kind of tumor different from either the primary endometrium carcinoma or ovary carcinoma, and usually can be detected in early stage with a good prognosis.

Publication types

  • English Abstract

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Endometrioid / pathology*
  • Carcinoma, Endometrioid / therapy
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • Cyclophosphamide / therapeutic use
  • Cystadenocarcinoma, Papillary / pathology
  • Cystadenocarcinoma, Papillary / therapy
  • Endometrial Neoplasms / pathology*
  • Endometrial Neoplasms / therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Hysterectomy
  • Middle Aged
  • Neoplasms, Multiple Primary / pathology*
  • Neoplasms, Multiple Primary / therapy
  • Ovarian Neoplasms / pathology*
  • Ovarian Neoplasms / therapy
  • Retrospective Studies
  • Survival Analysis

Substances

  • Cyclophosphamide
  • Cisplatin

Supplementary concepts

  • CP protocol